13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BLU GIST

    Acronym: 

    VOYAGER

    ACTRN/NCT /ethics: 

    NCT03465722

    Scientific title: 

    Study of Avapritinib (BLU-285) vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

    Summary of trial and patient characteristics

    Cancer Type Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase III Tumour Stream Gastrointestinal Stromal Tumour (GIST)
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2021-03-26
    Molecular Target Anticipated End Date 2023-04-01
    Cancer Type Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Gastrointestinal Stromal Tumour (GIST)
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2021-03-26
    Anticipated End Date 2023-04-01

    Trial Summary

    This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.

    Lay Summary

    Study of Avapritinib (BLU-285) vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

    Sponsor / Cooperative group

    Blueprint Medicines Corporation

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Amitesh Roy Recruiting